According to study results published in Biologics: Targets and Therapy, more than 50% of ankylosing spondylitis patients treated with 50 mg. Enbrel weekly achieved remission. It was also notable that a high percentage of patients were able to maintain remission when their dose was administered every other week.
The study involved 78 ankylosing spondylitis patients who were treated with 50 mg. Enbrel weekly between 2005 and 2009. Patients in remission had BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) scores below 4, no extra-axial evidence of peripheral arthritis, dactylitis, tenosynovitis, or iridocyclitis. They also had normal CRP and sedimentation rate results. In 2010, 43 patients who achieved remission were assigned to one of two treatment groups: 50 mg. Enbrel weekly or every other week. Roughy 86% of the biweekly group and 90% of the weekly group maintained remission.
Being able to maintain remission on a lower dose would have significant benefits for the patient, including less cost and less exposure to side effects.
Photo by Kai Koehler (iStockphoto)